Russia's first Covid-19 vaccine trails to begin on 40,000 people next week

Mass testing of Russia's first potential Covid-19 vaccine to get domestic regulatory approval will involve more than 40,000 people and will be overseen by a foreign research body when it starts next week, backers of the project said on Thursday.

These were the first details on the shape and size of the upcoming late-stage trial of the vaccine given by its developers, who are aiming to allay concerns among some scientists about the lack of data provided by Russia so far.

The vaccine, called "Sputnik V" in homage to the world's first satellite launched by the Soviet Union, has been hailed as safe and effective by Russian authorities and scientists following two months of small-scale human trials, the results of which have not been made public yet.

But Western experts have been more sceptical, warning against its use until all internationally approved testing and regulatory steps have been seen to be taken and proved a success.

"A range of countries is running an information war against the Russian vaccine," Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF) that is backing the vaccine, told a briefing.

The vaccine data will



be published in an academic journal later this month, he said.

Russia has received requests for up to a billion doses of the vaccine from around the world and has capacity to produce 500 million doses per year via manufacturing partnerships, he said.

A director at Moscow's Gamaleya Institute, which developed the vaccine, said 40,000 people would be involved in the mass testing at more than 45 medical centres around Russia.

The data is being provided to the World Health Organization (WHO), Dmitriev said, and to several countries that are considering participating in the late-stage trial, including the United Arab Emirates, India, Brazil, Saudi Arabia and the Philippines.

Sputnik V has already received approval from domestic regulators, leading President Vladimir Putin and other officials to name Russia the first country to license a Covid-19 vaccine.

The registration took place, however, ahead of the start of the large-scale trial, commonly known as a Phase III trial, considered by many as a necessary precursor to registration. At least four other potential Covid-19 vaccines are currently in Phase III trials globally, according to WHO records.